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The neuronal-ceroid lipofuscinoses (NCLs; often referred to as Battens 
Disease) are a group of hereditary disorders of childhood. Symptoms of NCLs 
are characterized by neurodegeneration with progressive neural cell death in 
the retina and central nervous system (CNS). The infantile form of NCL 
results from a deficiency in the protein, palmitoyl protein thioesterase-1 
(PPT-1). PPT-1, encoded by the Cln1 gene, removes long chain fatty acids from 
modified cysteine residues in proteins. Mutations in the Cln1 gene are 
associated with an accumulation of autofluorescent lysosomal lipopigments in 
various tissues such as the retina and CNS. In the current study, we use a 
transgenic mouse model in which the gene for Cln1 has been mutated, i.e., 
'knocked out'. Our goal is to perform histological experiments to assess the 
functional progression of neurodegenerative changes in the retina, brain and 
spinal cord as the subject ages. The retina, brain and spinal cord of the 
mice at different ages were fixed and embedded in plastic resin and/or 
paraffin. Thick sections (1 mm or 10 mm, respectively) were stained with 
toluidine blue or propidium iodide to detect neuronal loss and/or apoptosis 
as a result of the PPT-1 deficiency. Fluorescent images of the stained 
sections were obtained to document changes in tissue structure and the extent 
of degeneration. These studies provide information that will aid future 
studies in which stem cell transplants will be made into the Cln1 knockout 
mouse model. Ultimately, this approach will determine whether combined gene 
and stem cell therapies can be applied to patients with Battens Disease. 
 
